Opioid use disorder psychedelic and ketamine research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
20 registered studies are counted for opioid use disorder. By compound: 9 psilocybin, 1 MDMA, 1 LSD, 7 ketamine and 3 ibogaine. By registry status: 11 recruiting, 1 not yet recruiting, 3 completed, 3 terminated and 2 withdrawn. By phase: 5 phase 1, 14 phase 2 and 1 not reported. Reported start years run from 2020 (earliest) to 2027 (latest).
Studies are matched when the title names opioid use disorder, opioid or opiate dependence, addiction or withdrawal, opioid users or heroin. Studies of opioid receptor mechanisms in other conditions are not matched. Studies are matched by keyword on the title as registered, so a study can be missed and a study that mentions the condition only in passing can be included. A study tagged with more than one compound is counted under each compound. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 20 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 9 |
| MDMA | 1 |
| LSD | 1 |
| Ketamine | 7 |
| Ibogaine | 3 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 11 | 55% |
| Not yet recruiting | 1 | 5% |
| Completed | 3 | 15% |
| Terminated | 3 | 15% |
| Withdrawn | 2 | 10% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 1 | 5 | 25% |
| Phase 2 | 14 | 70% |
| Not reported | 1 | 5% |
Countries
Country is taken from the study's linked research site. 0 of 20 records have no country on file. The top 4 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 17 | 85% |
| Canada | 1 | 5% |
| Spain | 1 | 5% |
| United Kingdom | 1 | 5% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 12 |
| 2020 to 2023 | 8 |
Study design
- 19 interventional and 1 observational studies.
- Median planned or actual enrolment is 21 participants (range 4 to 480, across 19 records that report it).
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder | NCT06005662 | Withdrawn | Phase 2 | 2027-04-01 | Psilocybin |
| Targeting Treatment-Resistant OUD With Ketamine-Assisted Mindfulness Oriented Recovery Enhancement | NCT07369089 | Not yet recruiting | Phase 2 | 2026-02-01 | Ketamine |
| Ketamine for Opioid Use Disorder | NCT06943859 | Recruiting | Phase 2 | 2026-01-01 | Ketamine |
| Psilocybin on Brain Mechanisms of Motivation in OUD | NCT06810310 | Recruiting | Phase 2 | 2025-12-22 | Psilocybin |
| Psilocybin for Opioid Use Disorder (OUD) | NCT06796062 | Recruiting | Phase 2 | 2025-12-17 | Psilocybin |
| Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication | NCT05585229 | Recruiting | Phase 2 | 2025-10-27 | Psilocybin |
| Wellcome Leap Psilocybin for OUD | NCT06786325 | Recruiting | Phase 2 | 2025-10-07 | Psilocybin |
| Mapping Ibogaine Neural Dynamics in Opioid Use Disorder | NCT07226570 | Recruiting | Not reported | 2025-09-08 | Ibogaine |
| Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD) | NCT06160284 | Recruiting | Phase 1 | 2025-05-28 | Psilocybin |
| Ketamine for OUD and Suicidal Ideation in the ED | NCT06111339 | Terminated | Phase 2 | 2024-06-14 | Ketamine |
| MDMA for Co-occurring PTSD and OUD After Childbirth | NCT05219175 | Recruiting | Phase 2 | 2024-04-16 | MDMA, LSD |
| Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder | NCT06067737 | Recruiting | Phase 2 | 2024-02-08 | Psilocybin |
| Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use | NCT05242029 | Withdrawn | Phase 2 | 2023-12-01 | Psilocybin |
| Ketamine for OUD and Comorbid Depression (OUDCD) | NCT05051449 | Terminated | Phase 1 | 2022-04-04 | Ketamine |
| KAP for Depression in Abstinent Opioid Users | NCT05193318 | Terminated | Phase 2 | 2022-01-13 | Ketamine |
| Ketamine Assisted Psychotherapy for Opioid Use Disorder | NCT04892251 | Recruiting | Phase 1 | 2021-05-20 | Ketamine |
| A Study of Oral Ibogaine in Opioid Withdrawal | NCT05029401 | Completed | Phase 1 | 2021-04-01 | Ibogaine |
| Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine | NCT04161066 | Recruiting | Phase 1 | 2021-01-13 | Psilocybin |
| Ketamine for the Treatment of Opioid Use Disorder and Depression | NCT04177706 | Completed | Phase 2 | 2020-12-17 | Ketamine |
| Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification | NCT04003948 | Completed | Phase 2 | 2020-10-28 | Ibogaine |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | MDMA | LSD | Ketamine | Ibogaine
Other condition hubs
Depression | Treatment-resistant depression | Bipolar disorder | Post-traumatic stress disorder | Alcohol use disorder | Tobacco and nicotine use | Cocaine and methamphetamine use | Anxiety | Cancer and end-of-life distress | Obsessive-compulsive disorder | Eating disorders | Headache and migraine | Chronic pain | Suicidal ideation and suicide risk